Showing results (11-20 of 71) with videos related to
Sort By:
Pageof 8
Journal of Clinical Medicine|July 24, 2021
The Tacrolimus Metabolism Rate and Dyslipidemia after Kidney TransplantationGerold Thölking, Christian Schulte, Ulrich Jehn, et al.Scientific Reports|December 30, 2020
Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantationUlrich Jehn, Katharina Schütte-Nütgen, Joachim Bautz, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|May 22, 2003
Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipientsBarbara Suwelack, Viola Kobelt, Matthias Erfmann, et al.Journal of Clinical Medicine|November 7, 2019
Correction: Fast Tac Metabolizers at Risk-It is Time for a C/D Ratio Calculation. <i>J. Clin. Med.</i> 2019, <i>8</i>, 587Katharina Schütte-Nütgen, Gerold Thölking, Julia Steinke, et al.Journal of Clinical Medicine|May 8, 2020
Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and RecipientsUlrich Jehn, Katharina Schütte-Nütgen, Ute Henke, et al.Journal of Clinical Medicine|March 10, 2022
Improved Kidney Allograft Function after Early Conversion of Fast IR-Tac Metabolizers to LCP-TacGerold Thölking, Filiz Tosun-Koç, Ulrich Jehn, et al.Trials|February 19, 2016
Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trialClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.Kidney International|December 26, 2021
Results of the prospective multicenter SoLKiD cohort study indicate bio-psycho-social outcome risks to kidney donors 12 months after donationBarbara Suwelack, Klaus Berger, Heiner Wolters, et al.Journal of Clinical Medicine|May 1, 2019
Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio CalculationKatharina Schütte-Nütgen, Gerold Thölking, Julia Steinke, et al.Journal of Clinical Medicine|January 26, 2020
Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers After Renal TransplantationGerold Thölking, Nils Hendrik Gillhaus, Katharina Schütte-Nütgen, et al.Pageof 8